NeoNavia AB is a privately held, founder-led Swedish MedTech company focused on advancing breast cancer diagnostics. Its first product, the NeoNavia Biopsy System, is an innovative breast biopsy solution that combines advanced needle insertion technology with superior sampling efficiency, ensuring precision and diagnostic reliability. With regulatory approvals in the EU and the US, NeoNavia is driving innovation and shaping the future of minimally invasive breast biopsy procedures.